Pharma BD Deal Intelligence
A tiny, undisclosed 2005 antibody-tech tuck-in that was quietly absorbed into Pfizer's biologics engineering toolkit — no product, revenue, or writedown ever publicly tied to it, 20 years on.
Full analysis, sources & comparables →Bay City Capital described Bioren as utilizing its 'patented Walk Through Mutagenesis (WTM) technology to design antibodies in an in vitro and fully automated…
Pfizer SVP Worldwide Research Technology Nick Saccomano said the acquisition would 'strengthen Pfizer's commitment to the antibody space,' adding 'the ability…
The Pharma Letter framed the deal as Pfizer absorbing a privately-held antibody-engineering specialist from Bay City Capital, undisclosed terms, with…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer acquires Bioren (antibody discovery; Walk Through Mutagenesis platform) from Bay City Capital. Terms undisclosed.
A tiny, undisclosed 2005 antibody-tech tuck-in that was quietly absorbed into Pfizer's biologics engineering toolkit — no product, revenue, or writedown ever publicly tied to it, 20 years on.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Bioren, Inc. (this deal) | 2005 | — | 43 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2005 deals · Pfizer Inc. deals